CLINICAL TRIALS PROFILE FOR NASONEX
✉ Email this page to a colleague
505(b)(2) Clinical Trials for NASONEX
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT00779740 ↗ | Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2005-02-01 | This is a multicenter, open-label, randomized, parallel group comparison study to verify the clinical equivalency of the old formulation (50 mcg as mometasone furoate [MF] in 50 μL of solution per spray) to the new formulation (50 mcg as MF in 100 μL of solution per spray) in patients with perennial allergic rhinitis. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for NASONEX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00070707 ↗ | Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280) | Completed | Integrated Therapeutics Group | Phase 4 | 2003-04-03 | This study will compare mometasone nasal spray to placebo in treating the nasal and asthma symptoms experienced by participants with seasonal allergic rhinitis (SAR) and concomitant asthma. |
| NCT00070707 ↗ | Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2003-04-03 | This study will compare mometasone nasal spray to placebo in treating the nasal and asthma symptoms experienced by participants with seasonal allergic rhinitis (SAR) and concomitant asthma. |
| NCT00117611 ↗ | Xolair in Patients With Chronic Sinusitis | Completed | Genentech, Inc. | Phase 4 | 2005-07-01 | The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis. |
| NCT00117611 ↗ | Xolair in Patients With Chronic Sinusitis | Completed | Novartis Pharmaceuticals | Phase 4 | 2005-07-01 | The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis. |
| NCT00117611 ↗ | Xolair in Patients With Chronic Sinusitis | Completed | University of Chicago | Phase 4 | 2005-07-01 | The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis. |
| NCT00224523 ↗ | Long Term Safety Of GW685698X Via Nasal Biopsy | Completed | GlaxoSmithKline | Phase 3 | 2005-09-01 | Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with perennial allergic rhinitis . Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. Perennial allergic rhinitis is triggered by house dust mites, animal dander, etc., possibly causing symptoms year-round including nasal congestion, rhinorrhea and/or nasal itching. |
| NCT00359216 ↗ | The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2006-05-01 | This is a Phase 4 randomized, placebo-controlled, parallel-group, single-center, double-blind study to evaluate the effects of mometasone furoate nasal spray (MFNS) in subjects with Sleep-disordered Breathing (SDB) associated with perennial allergic rhinitis (PAR) using Peak Nasal Inspiratory Flow (PNIF), Embletta device home-monitored cardiopulmonary evaluations, and rhinitis evaluations and questionnaires. Approximately 30 subjects 18 to 60 years of age with symptomatic PAR (with or without SAR) will be selected and randomized at one study site. The anticipated duration of subject participation in the study is approximately 39 days. Subjects who qualify at the Screening Visit will complete a 10-14 day run-in/screening period. Following the run-in period, subjects who meet the qualifications at the Baseline Visit will be treated with study medication for 4 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NASONEX
Condition Name
Clinical Trial Locations for NASONEX
Trials by Country
Clinical Trial Progress for NASONEX
Clinical Trial Phase
Clinical Trial Sponsors for NASONEX
Sponsor Name
